<DOC>
	<DOCNO>NCT02674750</DOCNO>
	<brief_summary>This Phase 2 , open-label , multicenter trial design evaluate efficacy safety CUDC-907 subject 18 year old Relapsed/Refractory ( RR ) MYC-altered Diffuse Large B-Cell Lymphoma ( DLBCL ) .</brief_summary>
	<brief_title>Study Evaluate Efficacy Safety CUDC-907 Patients With RR DLBCL , Including Patients With MYC Alterations</brief_title>
	<detailed_description>Patients RR DLBCL eligible treatment CUDC-907 , long tumor tissue available test MYC-altered disease base one following : - Fresh tumor tissue obtain biopsy accessible lesion , - Archived tumor tissue ( recent available ) Subjects require submit archival tumor sample ( recent available ) fresh tumor sample central FISH IHC test . Subjects whose tumor previously characterize MYC-altered strongly encourage enter study . For subject enter study unconfirmed MYC-altered disease , fresh tumor sample prefer .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>1 . Age ≥ 18 year . 2 . At least 2 4 prior line therapy treatment de novo DLBCL ineligible ( fail ) autologous allogeneic stem cell transplant ( SCT ) ( salvage therapy , condition therapy maintenance transplant consider one prior treatment ) . NOTE : For follicular lymphoma transform DLBCL ( tFL/DLBCL ) , single agent noncytotoxic therapy consider line therapy . 3 . Histopathologically confirm diagnosis one following : RR DLBCL per 2008 World Health Organization ( WHO ) classification hematopoietic lymphoid tumor ( Swerdlow et al , 2008 ) . High grade Bcell lymphoma ( HGBL ) , MYC BCL2 and/or BCL6 rearrangement DLBCL , NOS per 2016 revision WHO classification lymphoid neoplasm ( Swerdlow et al , 2016 ) . Diagnosis tFL/DLBCL allow . However , Bcell lymphomas include transform indolent lymphomas/DLBCL per 2008 WHO classification , Burkitt lymphoma eligible . 1 . Known primary mediastinal , ocular , epidural , testicular breast DLBCL . 2 . Active CNS involvement malignancy . 3 . Known allergy hypersensitivity phosphatidylinositol 3 kinase ( PI3K ) inhibitor component formulation use study . 4 . Cytotoxic anticancer therapy ( e.g. , alkylating agent , antimetabolite , purine analogue ) systemic anticancer therapy within 2 week study entry . 5 . Radiotherapy deliver nontarget lesion within one week prior start study treatment deliver target lesion follow study ( note : prior site radiation record ) . 6 . Treatment experimental therapy within 5 terminal halflives ( t1/2 ) 4 week prior enrollment , whichever longer . 7 . Current plan glucocorticoid therapy , follow exception : Doses ≤ 10 mg/kg/day prednisolone equivalent allow , provide steroid dose stable taper least 14 day prior first dose CUDC907 . Inhaled , intranasal , intraarticular , topical steroid permit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>MYC</keyword>
</DOC>